Symbols

KNSA

Kiniksa·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 0

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About KNSA

Kiniksa Pharmaceuticals International, Plc

A company that developing drugs for recurrent pericarditis and cardiovascular disease

Industry

Pharmaceutical

Established Date

07/21/2015

Listing Date

05/24/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

366

Fiscal Year Ends

12-31

Website

www.kiniksa.com

Security Type

Common stock

Office address

105 Piccadilly, Second Floor, London, W1J 7NJ, England, United Kingdom

Business

Introduction

Kiniksa Pharmaceuticals International, plc was established in Bermuda on July 21, 2015. The company changed its registration from Bermuda to the United Kingdom on June 28, 2024. The Company is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic drugs for patients with debilitating diseases with serious unmet medical needs. The company's immunomodulatory combinations ARCALYST, KPL-404 and mavrilimumab target a range of undertreated cardiovascular and autoimmune diseases based on strong biological principles or proven mechanisms, and offer the potential for differentiation.

Company Financials

EPS

KNSA has released its 2025 Q4 earnings. EPS was reported at 0.17, versus the expected 0.35, missing expectations. The chart below visualizes how KNSA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

KNSA has released its 2025 Q4 earnings report, with revenue of 202.13M, reflecting a YoY change of 64.95%, and net profit of 14.20M, showing a YoY change of 259.75%. The Sankey diagram below clearly presents KNSA's revenue sources and cost distribution.